Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

被引：0
|
作者：
Wang, Yakun
Wang, Chang
Chen, Xiaofeng
Peng, Zhi
Gu, Yanhong
Wang, Yizhuo
Wang, Xicheng
Li, Jian
Gong, Jifang
Qi, Changsong
Yuan, Jiajia
Lu, Zhihao
Lu, Ming
Shen, Lin
Cao, Yanshuo
Zhang, Xiaotian
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Canc Ctr, Changchun, Jilin, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Oncol Dept, Nanjing, Jiangsu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Early Drug Dev Ctr, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Early Drug Dev Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-244-3829; 283-9769-3573-426; 261-492-3532-2370-7650-2700; 3282-270-434-6184; 261-492-3532-2370-5109; 261-492-2769; 261-566-11347; 4; 3; 2; 3599; 239; 2950; 2425; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [1] PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
    Yakun Wang
    Jialin Lu
    Xiaoyi Chong
    Chang Wang
    Xiaofeng Chen
    Zhi Peng
    Yanhong Gu
    Yizhuo Wang
    Xicheng Wang
    Jian Li
    Jifang Gong
    Changsong Qi
    Jiajia Yuan
    Zhihao Lu
    Ming Lu
    Jun Zhou
    Yanshuo Cao
    Yang Chen
    Cheng Zhang
    Zhiguo Hou
    Hongyi Kou
    Lin Shen
    Xiaotian Zhang
    Signal Transduction and Targeted Therapy, 10 (1)
  • [2] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
    Chen, Xiaofeng
    Xu, Hao
    Wang, Deqiang
    Chen, Xiaobing
    Wang, Kangxin
    Jin, Guangfu
    Ding, Yongbin
    Tang, Jie
    Fang, Yueyu
    Sun, Hui
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    Guo, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 365 - 365
  • [3] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose-escalation and expansion study.
    Chen, Xiaofeng
    Ding, Yongbin
    Wang, Deqiang
    Wang, Kangxin
    Xu, Hao
    Tang, Jie
    Li, Wei
    Fang, Yueyu
    Sun, Hui
    Liu, Liang
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16053 - E16053
  • [4] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Wang, Junyun
    Zhu, Mingyue
    Bai, Zhigang
    Zhao, Baoyi
    Zhang, Jun
    Yin, Jie
    Yang, Xiaobao
    Liu, Zongzhi
    Zhang, Zhongtao
    Deng, Wei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2597 - 2608
  • [5] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Chao Jing
    Junyun Wang
    Mingyue Zhu
    Zhigang Bai
    Baoyi Zhao
    Jun Zhang
    Jie Yin
    Xiaobao Yang
    Zongzhi Liu
    Zhongtao Zhang
    Wei Deng
    Cancer Immunology, Immunotherapy, 2022, 71 : 2597 - 2608
  • [6] Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Le Zhang
    Weixue Wang
    Shaohua Ge
    Hongli Li
    Ming Bai
    Jingjing Duan
    Yuchong Yang
    Tao Ning
    Rui Liu
    Xia Wang
    Zhi Ji
    Feixue Wang
    Haiyang Zhang
    Yi Ba
    Ting Deng
    BMC Cancer, 23
  • [7] Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
    Wang, Huaying
    Tian, Wenjuan
    Ren, Yulan
    Jing, Chuyu
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Zhang, Le
    Wang, Weixue
    Ge, Shaohua
    Li, Hongli
    Bai, Ming
    Duan, Jingjing
    Yang, Yuchong
    Ning, Tao
    Liu, Rui
    Wang, Xia
    Ji, Zhi
    Wang, Feixue
    Zhang, Haiyang
    Ba, Yi
    Deng, Ting
    BMC CANCER, 2023, 23 (01)
  • [9] Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.
    Jian, Zhou
    Fan, Jia
    Shi, Guo-Ming
    Huang, Xiao-Yong
    Wu, Dong
    Liang, Fei
    Yang, Guo-Huan
    Lu, Jia-Cheng
    Chen, Yi
    Ge, Ning-Ling
    Ji, Yuan
    Hou, Y. Y.
    Sun, Hui-Chuan
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Huang, Xiao-Wu
    Shi, Ying-Hong
    Gao, Qiang
    Yang, Xin-Rong
    Wang, Xiao-Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.
    Zhu, Wenyu
    Chu, Yunqian
    He, Xuan
    Jiang, Hua
    Zhu, Chan
    Zhang, Xing
    Wu, Fangfang
    Dai, Hanjue
    Xian, Qingying
    Xue, Ya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345